Needham analyst Ami Fadia initiated coverage of Day One Biopharmaceuticals with a Buy rating and $40 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DAWN:
- Day One Biopharmaceuticals initiated with a Buy at Goldman Sachs
- Day One Biopharmaceuticals initiated with a Buy, $34 price target at BofA
- Day One Biopharmaceuticals initiated with a Buy at BofA
- Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
- Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting